1Ganinat J,Monller H.Postopertive delirium:risk facter,prophylaxis and teatment[J].Ansesthssist, 1999,48 : 507-518.
2Street JS,Clark WS.Gannon KS,et al.Olamapine in treatment of psy-chotie and behavioral symptoms in patients with Alzheimer disease in nursing care facilities[J].Arch Gen Psychiatry,2000,57.
4Beasley CM Jr, Tollefson GD, Tran PV. Efficacy of olanzapine: an overview of pivotal clinical trials[ J~. J Clin Psychiatry, 1997, 58(10) :7 - 12.
5Beasley CM Jr, Tollefson GD, Tran PV. Safety of olanzapine[J]. Clin Psychiatry, 1997,58(10) :13 - 17.
6Beasley CM Jr, Hamilton SH, Crawford AM, et al. Olanzapine versus haloperidol: acute phase results of the international double -blind olanzapine trial [ J ]. Fur Neuropsychopharmacology, 1997,7:125 - 137.
7Beasley CM Jr, Tollefson GD, Tran P, et al. Olanzapine versus placebo and baloperidol : acute phase results of the North American double - blind olanzapine trial [ J ]. Nearopsychopharmacology, 1996,14:111 - 123.
8Tollefson GD, Beasley CM Jr, Tran PV, et al. Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective and schizophreniferm disorders : results of an international collaborative trial[ J]. Am J Psychiatry, 1997,154:457 - 465.
9Beasley CM Jr, Sanger T, Satterlee W, et al. Olanzapine versus placebo : results of a double - blind, fixed - dose olanzapine trial [ J]. Psychopharmacology, 1996,124 : 159 - 167.
10Tollefson GD, Beasley CM Jr, Tamura RN, et al. Blind, controlled, long - term study of the comparative incidence of treatment - emergent tardive dyskinesia with olanzapine or haloperidol [ J]. Am J Psychiatry, 1997,154 : 1248 - 1254.
